What is the mechanism of action of Opicapone? How to help treat related conditions

Opicapone (Opicapone) is a selective, long-acting COMT inhibitor (catechol-O- methyltransferase inhibitor) used to treat Parkinson's disease. Its mechanism of action is mainly by inhibiting the activity of COMT enzyme, prolonging the action time of levodopa, and improving the motor symptoms of patients with Parkinson's disease. Here’s a closer look at how Opicapone works and how it can help treat related conditions.

Opicapone works by inhibiting COMT (catechol-O-methyltransferase). COMTThe enzyme is involved in metabolizing levodopa (levodopa). It converts levodopa into 3-O-methyllevodopa. This metabolic process reduces the efficacy of the drug. In patients with Parkinson's disease, levodopa is the main treatment drug and can effectively improve motor symptoms. However, levodopa is rapidly metabolized by the COMT enzyme in the body, resulting in a shortened half-life and thus affecting the efficacy. Opicapone reduces the metabolism of levodopa by selectively inhibiting the COMT enzyme, allowing more levodopa to be effectively utilized in the body, thus prolonging the efficacy of the drug.

The use of Opicapone can significantly improve the quality of life of patients with Parkinson's disease. When used in combination with traditional levodopa therapy, it can increase the blood concentration of levodopa and reduce motor symptoms such as tremor, stiffness and bradykinesia in patients with Parkinson's disease. By reducing the rapid metabolism of levodopa, Opicapone can help patients maintain more stable drug levels and reduce the occurrence of "switching phenomena" (i.e. fluctuations in drug efficacy and recurrence of symptoms). This allows patients to experience more lasting and stable treatment effects in their daily lives.

Compared with otherCOMT inhibitors, opicapone has a longer duration of action and higher selectivity. It can effectively inhibit the COMT enzyme and prolong the half-life of levodopa, thereby reducing patients' motor symptoms caused by drug fluctuations. The long-acting nature of Opicapone allows it to be taken orally once a day, making it more convenient for patients to use without the need for frequent dosage adjustments. In addition, opicapone has relatively few side effects and can reduce common side effects such as gastrointestinal discomfort when used in combination with other anti-Parkinson's drugs.

Reference materials:https://www.ongentys.com/